SOUTH PLAINFIELD, NJ (December 16, 2008) -- “Today’s decision in our favor is important not just for PTC124, but for the future of the clinical trial process for all experimental drugs for rare disease.

“We continue to believe our approach to the development of PTC124 is in the best interests of all boys suffering from this rare disease. The sooner we can complete the required clinical trials and get this drug approved, the sooner all who suffer from the type of Duchenne Muscular Dystrophy (DMD) addressed by PTC124 may benefit.”